Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects
NCT ID: NCT05212259
Last Updated: 2022-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
375 participants
INTERVENTIONAL
2022-10-10
2023-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis
NCT06917287
Evaluation of the Effect of a Food Supplement Based on Hydrolyzed Collagen on Joint Function.
NCT05917925
To Assess the Efficacy of Collagen Supplement in Osteoarthritis
NCT04470336
Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
NCT06581094
Hydrolyzed Collagen in the Reduction of Osteoarticular Pain and Functional Limitation
NCT05149053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Collagen type II (40 mg/day)
4 capsules per day for 180 days
Collagen type II (40 mg/day)
4 capsules per day
Collagen type II (80 mg/day)
4 capsules per day for 180 days
Collagen type II (80mg/day)
4 capsules per day
Collagen type II (120 mg/day)
4 capsules per day for 180 days
Collagen type II (120 mg/day)
4 capsules per day
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
4 capsules per day for 180 days
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
4 capsules per day
Placebo
4 capsules per day for 180 days
Placebo
4 capsules per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collagen type II (40 mg/day)
4 capsules per day
Collagen type II (80mg/day)
4 capsules per day
Collagen type II (120 mg/day)
4 capsules per day
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
4 capsules per day
Placebo
4 capsules per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject with a history of 4-9 months related to knee joint pain aggravation on physical stress.
3. Body mass index (BMI) ≥ 20 and ≤ 29.9 kg/m2.
4. Fasting blood glucose (FBG) ≤ 125 mg/ dl.
5. Subject with self-reported joint pain of ≥ 70 mm on a 100-point VAS scale after 10±2 minutes of walking on a treadmill using modified Naughton protocol.
6. Subject with pain ≤30 mm at rest on Pain VAS
7. Subject not diagnosed as a case of OA / RA confirmed by the American college of rheumatology (ACR) criteria.
8. The subject is willing to complete all the study procedures including study-related questionnaires and tasks, and comply with the study requirements.
9. The subject is willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period.
10. Subject with the ability to read and provide written, personally signed, and dated informed consent to participate in the study.
Exclusion Criteria
2. Subject's inability to complete the exercise protocol of 10±2 minutes at screening.
3. Subject with the clinical diagnosis of any form of joint disease such as Osteoarthritis (OA).
4. Subject with the clinical diagnosis of any form of autoimmune disorder related to the joint such as Rheumatoid arthritis (RA).
5. A subject suffering from Insomnia and restless leg syndrome.
6. Uncontrolled hypertensive defined as subject currently on an anti-hypertensive drug with systolic Blood Pressure ≥ 140 mm Hg and/ or \& diastolic blood pressure ≥ 90 mm Hg
7. Uncontrolled diabetics currently on anti-diabetic medication with Fasting blood glucose (FBG) ≥ 126 mg/ dl.
8. Systolic Blood Pressure ≥ 140 mm Hg and/ or \& diastolic blood pressure ≥ 90 mm Hg
9. The subject who have been injured near the knee joint region in the past six months.
10. Subject with a history of knee surgery, replacement, or any non-knee surgical procedures that may impact the study outcomes.
11. The subject who have used Intra-articular injections and or steroids for joint health issues in the last six months. The subjects who have undergone a significant cardiovascular event in the past six months.
12. The subject who has undergone a significant cardiovascular event in the past six months.
13. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurological disorders, that in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
14. The subject who have any other chronic disease or condition or inflammatory disease conditions and/ or are using any medication or dietary supplements or ayurvedic medications or topical ointment/oil/gel for joint health that in the judgment of the Investigator would put the subject at unacceptable risk the for the subject in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
15. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
16. The subject who have participated in a study of an investigational product 90 days prior to the screening.
17. Subject with a history of heavy alcohol consumption.
18. Smokers
19. Subject currently on joint health supplements for pain or inflammation.
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HOS Hospital
Ahmedabad, Gujarat, India
Shalby hospital
Surat, Gujarat, India
Aman Hospital and Research Centre
Vadodara, Gujarat, India
BLDEU Hospital and research center
Vijayapura, Karnataka, India
Shree Ashirwad Hospital
Dombivali, Maharashtra, India
Surya Hospital
Nashik, Maharashtra, India
Ranka Hospital
Pune, Maharashtra, India
Jivanrekha Hospital
Pune, Maharashtra, India
BAJ RR Hospital
Thāne, Maharashtra, India
Jaipur National University Institute of Medical Sciences and Research Center
Jaipur, Rajasthan, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LZ/210901/UCII/RMJD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.